智通财经APP讯，中国同辐(01763)发布公告，根据对本集团截至2025年12月31日止年度的未经审核综合 管理账目及现时可得数据之初步审阅，预期与2024年同期相比：收益预计约人民币69.79亿元至人民币 72.06亿元，同比减少约5%至8%;净利润预计约人民币6.11亿元至人民币6.55亿元，同比减少约25%至 30%;本公司权益股东应占年内利润预计约人民币3.02亿元至人民币3.22亿元，同比减少约20%至25%。 截至目前，公司经营运作正常，2025年度收益减少主要由于本集团的核医疗装备分部收益下降，利润减 少主要由于本公司附属公司深圳市中核海得威生物科技有限公司补缴税费及滞纳金影响。 ...

Group 1 - The core transaction involved Aibo Medical, with a total of 35,000 shares traded on February 12, resulting in a transaction amount of 2.415 million yuan, which accounted for 2.37% of the total trading volume for that day [1][2] - The transaction price was set at 69 yuan per share, representing a premium of 15.1% over the market closing price of 59.95 yuan [1][2]

Group 1 - The core point of the article is that Chunli Medical (688236.SH) is currently trading at 22.12 yuan, reflecting a decline of 3.24% and is in a state of breaking its initial public offering price [1] - Chunli Medical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 30, 2021, with an initial offering price of 29.81 yuan and issued a total of 38.428 million shares [1] - The total amount raised during the IPO was 1.145 billion yuan, with a net amount of 1.067 billion yuan after deducting issuance costs, which was 932.8717 million yuan less than the originally planned net fundraising amount [1] Group 2 - The company intended to raise 2 billion yuan for various projects, including orthopedic implants and supporting materials, R&D center construction, marketing network development, and working capital [1] - The total issuance costs amounted to 78.4104 million yuan, with Huatai United Securities receiving a sponsorship fee of 1.5 million yuan and underwriting fees of 65.2359 million yuan [1]

Core Viewpoint - Aidi Te's dental industrial park construction is progressing as planned and is expected to commence production in the second half of this year, which will significantly enhance the company's overall capacity [1] Group 1: Company Development - The company is implementing a phased release of capacity in the new park based on market demand and order forecasts to ensure a precise match between capacity release and order growth [1] - The company aims to ensure that the newly added capacity is efficiently utilized and orderly digested [1]

Core Insights - The company is focusing on new product launches, expansion into overseas markets, and obtaining medical device registrations for its subsidiaries [1] Product Development Progress - The second-generation bipolar product line is expected to receive regulatory approval by the end of 2025 and aims for full market promotion in 2026, which is anticipated to become a new growth driver [2] Business Progress - North American sales are expected to experience fluctuations due to tariff policies, but the company is advancing its shipping plans through its Thailand factory and plans to gradually expand to other overseas regions [3] Subsidiary Development - The company's controlling subsidiary received three Class II medical device registrations in December 2025, covering endoscopic equipment, with a validity period until December 2030, which will help enrich the product line, although the impact on future performance remains uncertain [4]

Company Performance - The company's stock price has shown a downward adjustment, with a decline of 3.95% over the past 7 days, and a single-day drop of 3.24% on February 12, closing at 22.12 yuan [1][2] - Despite significant growth in revenue and net profit, with a year-on-year increase of 213.21% in net profit attributable to the parent company, the positive performance has not alleviated short-term negative market sentiment [5] Industry Environment - The National Healthcare Security Administration reported typical cases of commercial bribery in the orthopedic field, revealing kickback ratios as high as 30%-40%, indicating a "golden sales" phenomenon in the industry [3] - Although leading companies, including the company in question, have generally forecasted revenue growth for 2025, there are concerns that regulatory actions may have a long-term impact on sales models and profitability within the industry [3] Market Sentiment - Despite a 16.56% increase in financing balance over the past 5 days, there was a net outflow of 337.38 thousand yuan in main funds on February 12, indicating a net selling state by large investors [4] - The stock has experienced a significant decline of 19.15% over the past 20 days, reflecting cautious market sentiment [4]

有投资者在互动平台向可孚医疗提问："董秘好，公司没有发布业绩预告，现在能否发布业绩快报，提 升投资者信心？" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 针对上述提问，可孚医疗回应称："尊敬的投资者，您好！公司严格按照相关法律法规及规范性文件的 规定履行信息披露义务，根据目前财务部门的初步测算，公司2025年度经营业绩未触及需披露业绩预告 或业绩快报的情形，因此无需披露相关业绩预告或业绩快报。公司2025年年度报告预约披露时间为2026 年3月10日，具体经营及财务数据请以届时公司在指定信息披露媒体披露的定期报告为准。感谢您的关 注。" ...

经济观察网归创通桥发布正面盈利预告，预期2025年净利润超过人民币2.4亿元，同比增长约139.4%， 营收超过10.5亿元，同比增长约34.6%。根据港股规则，公司需在近期内披露经审计的完整年度报告。 产品研发进展 通桥麒麟血流导向装置、ZYLOX Swan静脉导管等产品2025年销售表现强劲，且颈动脉双层密网支架等 创新产品已进入国家药监局"绿色通道"。新产品获批上市及现有产品在集采环境下的放量情况可能成为 市场焦点。 股票近期走势 受盈喜及国际化进展催化，2026年2月3日公司股价单日涨近7%，成交额达1788万港元。若业绩正式报 告超预期或战略布局传出新进展，可能进一步影响短期市场情绪。 以上内容基于公开资料整理，不构成投资建议。 业绩经营情况 归创通桥于2026年1月29日发布正面盈利预告，预期2025年净利润超过人民币2.4亿元，营收超过10.5亿 元。根据港股规则，盈喜后公司需在近期内披露经审计的完整年度报告，具体时间可能于2026年3月前 公布。 业务进展情况 2026年1月，公司宣布战略收购德国Optimed公司，以加速欧洲市场渗透；截至2025年底，其销售渠道已 覆盖83个国家，海外收入同 ...

Core Viewpoint - The company has successfully achieved mass production of its surgical robots, which integrate advanced intelligent technologies and have received regulatory certifications for various orthopedic procedures [1] Group 1: Product Development - The company has obtained regulatory certifications for hip, knee, and unicompartmental surgical robots, indicating readiness for market deployment [1] - The surgical robots provide a comprehensive digital orthopedic solution covering pre-operative, intra-operative, and post-operative stages [1] Group 2: International Expansion - The company is actively responding to national "Belt and Road" policies and is steadily advancing its international business layout [1]

每经记者｜杜波 每经编辑｜陈柯名 记者|杜波 编辑|陈柯名 杜恒峰 校对|程鹏 2月12日A股收盘，主要指数集体收涨。沪指上涨0.05%，深成指上涨0.86%，创业板指上涨1.32%，科创综指上涨1.56%。总成交额2.16万亿元，较上一个 交易日放量1597亿元。 全市场超3200只个股下跌，超2100只个股上涨。盘面上，CPO概念大涨，太辰光、天孚通信、协创数据等多股涨超10%；电网设备概念走强，汉缆股份、 四方股份、望变电气等多股涨停；半导体板块拉升，芯原股份等大涨；影视院线板块延续回调，横店影视、博纳影业跌停。此外，通信设备、小金属、汽 车芯片、抽水储能、消费电子等概念涨幅居前，零售、白酒、乳业、预制菜、免税店等板块跌幅居前。 | < W | | 板块眼踪 | | 1 ( . | | --- | --- | --- | --- | --- | | 概念 | 行业 | 地域 | 风格 | 核心 | | 列表 ⇌ | | | 按今日 涨跌幅排序 | | | 光模块(CPO +5.81% | | 光芯片 +5.41% | 光电路交换机 +4.76% | 光通信 +4.10% | | AI算力 +3.95% ...